Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in hospitalized patients with COVID-19 pneumonia
PACTR202106466447805Phase 3Unknown
- Sponsor
- Genentech
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Genentech. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202106466447805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106466447805.